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Henoch-Schönlein Purpura (HSP) or IgA vasculitis is the most common systemic
vasculitis of childhood and may affect skin, joints, gastrointestinal tract, and kidneys. Skin
manifestations of HSP are characteristic and include a non-thrombocytopenic palpable
purpura of the lower extremities and buttocks. Rarely, HSP may initially present as or
evolve into hemorrhagic vesicles and bullae. We present an otherwise healthy 5-year-old
boy with an acute papulovesicular rash of both legs and intermittent abdominal pain. After
a few days the skin lesions rapidly evolved into palpable purpura and hemorrhagic bullous
lesions of variable size and severe hemorrhagic HSP was suspected. A histological
examination of a skin biopsy showed signs of a small vessel leukocytoclastic vasculitis
limited to the upper dermis and direct immunofluorescence analysis revealed IgA
deposits in vessel walls, compatible with HSP. To further characterize the clinical picture
and treatment options of bullous HSP we performed an extensive literature research and
identified 41 additional pediatric patients with bullous HSP. Two thirds of the reported
patients were treated with systemic corticosteroids, however, up to 25% of the reported
patients developed skin sequelae such as hyperpigmentation and/or scarring. The early
use of systemic corticosteroids has been discussed controversially and suggested in
some case series to be beneficial by reducing the extent of lesions and minimizing
sequelae of disease. Our patient was treated with systemic corticosteroids tapered over
5 weeks. Fading of inflammation resulted in healing of most erosions, however, a deep
necrosis developing from a large blister at the dorsum of the right foot persisted so that
autologous skin transplantation was performed. Re-examination 11months after disease
onset showed complete clinical remission with re-epithelialization but also scarring of
some affected areas.
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INTRODUCTION
Henoch-Schönlein Purpura (HSP) or IgA vasculitis is the most common systemic vasculitis
of childhood and may affect skin, joints, gastrointestinal tract, and kidneys (1). Skin manifestations
of HSP are characteristic and include a non-thrombocytopenic palpable purpura of the lower
extremities and buttocks. Rarely, HSP may initially present as or evolve into hemorrhagic
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vesicles and bullae resulting in cutaneous necrosis (2). We
present the case of a HSP patient with hemorrhagic-bullous skin
lesions and by summarizing additional reported cases aimed at
characterizing the clinical picture of bullous HSP and discussing
treatment options.
CASE REPORT
An otherwise healthy 5-year-old boy presented with an acute
papulovesicular rash of both legs (Figure 1a) and intermittent
abdominal pain. The patient did not have fever. Differential
blood count (white blood cell count of 12,900/µl with 60%
granulocytes and 29% lymphocytes), C-reactive protein (0.45
mg/dl), erythrocyte sedimentation rate (20 mm/h) and global
blood clotting tests (INR 0.98, PTT 31.5 s) were normal. Serum
IgA (147 mg/dl) and IgM (66 mg/dl) levels were within age
matched reference ranges whereas IgG levels were slightly
decreased (557 mg/dl, reference range 640-1420). No hematuria
or fecal occult blood could be detected. Abdominal ultrasound
could exclude intussusception but revealed thickened bowel wall
at the ileocecal junction. The abdominal symptoms resolved
spontaneously within 2 days but arthralgia appeared thereafter.
Nine days after the onset of disease the skin lesions at
the arms, legs, feet and ankles rapidly evolved into palpable
purpura and hemorrhagic-bullous lesions of variable size
ranging from 5 to 40mm (Figures 1b,c). Some of the blisters
spontaneously ruptured and disclosed hemorrhagic fluid which
remained sterile in the microbiological work-up. The patient was
given cefuroxime as antibiotic prophylaxis. Severe hemorrhagic-
bullous HSP was suspected but differential diagnoses included
septicemia/septic emboli and autoimmune blistering disease.
Absence of fever and leukocytosis and sterile blood cultures
argued against an infectious etiology. Neither circulating
antibodies directed against structural proteins of the basement-
membrane zone nor ANAs or ANCAs could be detected in
the patient‘s serum. C4 levels were in the normal range while
C3c levels were slightly elevated (152 mg/dl, reference range 80-
120). A skin biopsy was performed and histological examination
showed signs of a small vessel leukocytoclastic vasculitis limited
to the upper dermis (Figure 2), and direct immunofluorescence
analysis revealed IgA and C3 deposits in vessel walls, compatible
with HSP.
The patient was treated with oral corticosteroids
(prednisolone 1 mg/kg/day) for 7 days, then subsequently
tapered over 39 additional days. Although fading of
inflammation paralleled healing of most erosions, a deep
necrosis resulting from a large blister at the dorsum of the
right foot persisted (Figures 3a–c) so that autologous skin
transplantation was performed. Re-examination 11 months after
disease onset showed complete clinical remission of disease
with re-epithelialization but also scarring of some affected areas
(Figures 3d–f).
Abbreviations: DDEB, Dominant dystrophic epidermolysis bullosa; (HSP),
Henoch-Schönlein Purpura; HSV, Herpes simplex virus; MMP, matrix
metalloproteinase; RDEB, recessive dystrophic epidermolysis bullosa.
LITERATURE SEARCH
Skin manifestations of HSP are characteristic and include a non-
thrombocytopenic palpable purpura of the lower extremities
and buttocks (1). Rarely, HSP in children may initially present
as or evolve into hemorrhagic vesicles and bullae which may
result in necrosis of the skin and subsequently scarring (2). To
characterize bullous HSP in children we performed a literature
search and searched NCBI PubMed for publications using
“bullous purpura” as well as the combination of “bullous”
and “purpura.” In addition to our patient we identified 41
pediatric HSP patients with bullous skin lesions (Table S1) (3–
32). Included were 23 isolated case reports and 6 case series with
between 2 and 6 patients. We excluded two of these patients
from further analysis since both were later on diagnosed with
epidermolysis bullosa and might therefore have dual pathology.
We compared the clinical and demographic characteristics of
our and the remaining 39 patients (in total 40 patients) with
those reported in 4 separate cohorts of unselected pediatric
HSP patients using unpaired t-test for continuous variables and
Fisher‘s exact test for categorial variables (Table 1) (33–36). These
cohorts represent the complete clinical range of HSP, however,
due to their low prevalence, patients with bullous skin lesions do
not significantly contribute to the overall characteristics of these
cohorts.
The mean age of patients with bullous HSP patients at disease
onset was significantly higher compared with each of the four
cohorts of unselected HSP patients (Table 1). The prevalence of
joint, abdominal and renal involvement in bullous HSP patients
was comparable to that of the unselected HSP patient cohorts
(Table 1).
In all except two cohorts, bullous HSP patients were treated
more often with systemic corticosteroids than the average group
of HSP patients (Table 1). In addition, two (5.0%) out of the
40 bullous HSP patients were treated with colchicine, 3 (7.5%)
with azathioprine and one (2.5%) with dapsone (Table S1).
Three (7.5%) patients were treated with topical steroids and 11
(27.5%) did not receive any anti-inflammatory medical treatment
(Table S1).
Bullous lesions resolved in all 11 reported patients who did
not receive anti-inflammatory medical treatment and lesions did
not re-occur. Hyperpigmentation and/or scar formation has been
reported in 11 patients, in 10 of these despite medical treatment.
However, detailed information regarding skin sequelae including
explicit exclusion of scarring and/or hyperpigmentation
is missing in many of the reported patients (Table S1).
Interestingly, in 3 out of the 26 (11.5%) corticosteroid treated
bullous HSP patients, corticosteroid treatment was already
initiated up to 10 days before appearance of hemorrhagic-
bullous lesions, mainly due to abdominal involvement
(Table S1).
DISCUSSION
Palpable purpura mainly affecting the buttocks and legs
is the characteristic skin manifestations of HSP. The
differential diagnosis of these lesions include congenital (e.g.,
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FIGURE 1 | An acute papulovesicular rash of both legs (a) rapidly evolved into palpable purpura and hemorrhagic-bullous lesions of variable size ranging from 5 to
40mm (b,c).
FIGURE 2 | Skin biopsy of one lesion in H&E staining revealing signs of a small
vessel leukocytoclastic vasculitis limited to the upper dermis.
thrombocytopenia, hemophilia) or acquired (purpura fulminans,
disseminated intravascular coagulation) forms of bleeding
diathesis and other types of vasculitis (e.g., granulomatosis with
polyangiitis, eosinophilic granulomatosis with polyangiitis).
However, HSP may initially present as or evolve into
hemorrhagic vesicles and bullae progressing to cutaneous
necrosis which may lead to a diagnostic dilemma (2). The
differential diagnosis of blistering skin lesions includes infections
(e.g., HSV), toxins (e.g., staphylococcal scalded skin syndrome),
autoimmune diseases (e.g., pemphigus), genetic diseases
(e.g., epidermolysis bullosa) as well as physical pressure or
trauma (37).
Whereas, hemorrhagic-bullous lesions are rather common in
adult HSP patients, children with HSP less often develop this type
of lesions (<2%) (38). Due to the wide differential diagnosis, a
skin biopsy was performed in our presented case as it has been
done in more than half of the reported patients with bullous HSP
(Table S1). Histological analysis revealed signs of leucocytoclastic
vasculitis in all reported patients, however, IgA deposition could
not be detected in all patients (Table S1). This might be explained
by the time of biopsy, since deposition of IgA is more difficult to
detect in older lesions. Therefore, the biopsy should be obtained
from the border of a fresh non-bullous and non-necrotized
lesion where proteolytic degradation of IgA is less advanced. Skin
biopsy in our patient was performed 10 days after onset of the
first bullous lesion but targeted a lesion that evolved <2 days
before biopsy. Histological analysis of this skin biopsy revealed
the characteristic signs of leucocytoclastic vasculitis with IgA
deposition thereby confirming our tentative diagnosis of HSP in
or patient.
It has been speculated whether appearance of bullous lesions
reflects a more severe disease course or even a distinct disease
entity of HSP. The long-term prognosis in HSP is mainly
determined by the extent of renal involvement (39). However,
our literature review on bullous lesions in pediatric HSP revealed
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FIGURE 3 | Hemorrhagic bullae developed on both feet an lower legs (a–c). A deep necrosis resulting from a large blister at the dorsum of the right feet evolved (a,b)
neccessitating autologous skin transplantation. Re-examination 11 months after disease onset showed complete clinical remission of disease with re-epithelialization
of affected areas (d–f).
















Number (%) Number (%) Number (%) Number (%) Number (%)
Female 19 (46.3) 43 (43.0) 55 (36.6) 42 (53.8) 63 (47.0)
Age (years) 8.8 ± 3.4 5.9 ± 2.9* 6.1 ± 2.7* 6.2 ± 3.1* 6.3 ± 2.4*
Bullous lesions 40 (100) 2 (2.0) Not reported 1 (1.3) Not reported
Joint involvement 29 (70.5) 82 (82.0) 111 (74.0) 61 (78.2) 99 (73.9)
Abdominal involvement 23 (57.5) 63 (63.0) 77 (51.3) 57 (73.1) 96 (71.6)
Renal involvement 15 (37.5) 40 (40.0) 81 (54.0) 42 (53.8) 65 (48.5)
Corticosteroid use 26 (65.0) 57 (57.0) 19 (12.6) 18 (23.1)** 25 (18.7)**
Variables in each cohort were compared to those in reported cases with bullous HSP (*p < 0.01, **p < 0.001).
rather less renal involvement in this patient group and seems
to contradict this assumption. In most of the published patients
the bullous lesions resolved within a few weeks and did not
re-occur which led to the assumption of a rather benign and
self-limiting course of bullous HSP (2). However, remaining
hyperpigmentation and/or scarring have been reported in at
least 25% of the reported patients (14, 17, 20, 21, 27, 32). Since
information regarding skin sequelae in the disease course of
the reported patients is scarce and scarring has not explicitly
been excluded in many of the reported patients, the extent
of reported skin sequelae rather might be underestimated. In
contrast, re-occurrence of active disease has only been described
in very few individual cases of bullous HSP and most patients
followed a monophasic disease course. However, two patients
described to have clinical findings compatible with bullous
HSP suffered from re-occurrence of bullous skin lesions 1
and 2.5 years after onset of the first symptoms (16, 18) and
were later diagnosed with dominant dystrophic epidermolysis
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bullosa (DDEB) and recessive-dystrophic epidermolysis bullosa
(RDEB), respectively. Histological analysis of a skin biopsy
performed at first onset of bullous lesions in the patient
with DDEB revealed a non-inflammatory subepidermal bulla
in addition to the characteristic signs of leukocytoclastic
vasculitis.
The pathophysiology of blistering skin lesions in HSP still
remains unclear. Matrix metalloproteinase (MMP)-2 and MMP-
9 have been detected in blister fluid and suggested to cause
proteolysis of collagen (6). However, the triggers that drive the
secretion of these enzymes are not well-understood. Therefore,
future research should address the inflammatory mediators that
are involved in blister formation in HSP and might be targets of
more specific therapies. It might be speculated that bullous skin
lesions preferentially develop in HSP patients with intrinsic (e.g.,
genetic predisposition, general skin fragility) or extrinsic (e.g.,
physical skin pressure) risk factors but that the appearance of
bullous skin lesions does not mirror a distinct pathophysiology
of HSP itself.
The optimal treatment regime of patients with bullous HSP
is still controversial. The use of systemic corticosteroids in HSP
seems to shorten the abdominal pain and arthralgia and decrease
the prevalence of purpura (40, 41). Although corticosteroids
do not seem to hinder renal manifestation during the disease
course, they may reduce the risk of end-stage renal disease
(42, 43). There is no clear evidence for a beneficial use of systemic
corticosteroids in treating non-bullous skin lesions in HSP. Some
authors of published cases with bullous HSP suggested that early
systemic treatment with corticosteroids may be beneficial in
bullous HSP by promoting faster resolution of skin symptoms
and reducing scar formation (17). In contrast, the authors of
another systematic case review of patients with bullous HSP
concluded that patients with bullous HSP managed expectantly
and those managed with systemic steroids display a similar
disease course (2).
Whereas, resolution and absence of re-occurrence of lesions
has mainly been used as parameters to describe the diseases
course and response to therapy in most of the reported patients,
less attention has been paid to the potential sequelae of necrotic
skin lesions (scarring, hyperpigmentation). Of note, at least 25%
of the reported patients with bullous HSP developed some kind
of sequelae ranging from hyperpigmented skin areas to deep
necrosis necessitating autologous skin transplantation as in our
patient (Table S1).
Despite missing of strong evidence due to lack of randomized-
controlled trials in bullous HSP, it might be speculated that
corticosteroid treatment initiated very early in the disease
course of bullous HSP may reduce the severity of necrosis
and thereby the extent of skin sequelae. In contrast to this
assumption, evolution of bullous skin lesions in HSP patients
already receiving high-dose systemic steroids due to abdominal
involvement has been documented in 3 cases (7, 21, 22).
Additionally, 12 published patients with bullous HSP who
showed resolution of skin lesions did not receive any anti-
inflammatory medical treatment (3, 4, 6, 12, 14, 15, 18, 20, 28,
30). Although some of these did not develop scarring and/or
hyperpigmentation, explicit information about exclusion of skin
sequelae is missing in many of these patients. Of note, side effects
of systemic corticosteroid treatment have not been described in
any of the reported patients, which in our opinion additionally
favors the attempt of ameliorating the disease course by using
systemic corticosteroids early in the diseases course in bullous
HSP.
Steroid-sparing medication has been introduced in patients
with long-lasting disease course or inadequate responsiveness to
corticosteroids. These treatment regimens included colchicine,
azathioprine, or dapsone and have been described in only a few
cases (13, 20, 26, 27, 29). Despite the reported benefits in these
patients during treatment, the small number of published case
does not allow any general conclusion.
SUMMARY AND CONCLUDING REMARKS
- Hemorrhagic bullous skin lesions may rarely occur in
childhood HSP
- A diagnostic skin biopsy is helpful in the differential work-up
of these patients
- Blistering skin lesions in HSP do not generally seem to
be associated with more severe extracutaneous/systemic
involvement and might not have any prognostic value
- Most of the bullous skin lesions resolve within a few
weeks but may lead to necrosis resulting in scarring and/or
hyperpigmentation; re-occurrence of bullous lesions may hint
at an underlying disease
- The early use of systemic corticosteroids has been suggested in
bullous HSP patients but their beneficial effect on the extent of
lesions and/or the sequelae of disease has not been analyzed in
randomized controlled trials yet
- Supportive care (e.g., avoiding skin pressure, pain control,
antibiotic prophylaxis/treatment) is beneficial for all patients
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